Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Here is a story that ran in The Seattle Times a few days ago.

Seeking a fresh infusion of cash and global marketing expertise, ZymoGenetics cut a licensing deal with European pharmaceutical giant Bayer HealthCare to jointly deploy the Seattle biotechnology company's first expected product since it went public five years ago. ZymoGenetics said the agreement it is announcing today will bring $30 million upfront from Bayer and $40 million after the federal approval of rThrombin, which helps control surgical bleeding.

My only concern (if you read the entire article) is the part about Bayer getting the right to market rThrombin outside the U.S. indefinitely while only paying ZymoGenetics "up to 20 percent in royalties." I understand the reality involved, ZymoGenetics is just too small to take on a task that huge, but the greedy side of me is asking "you couldn't do better than 20%???" 60/40 I'd be fine with, but 80/20? We'll see how it turns out.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.